Quantisnow Logo
Dashboard

Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting

$SENS
Industrial Machinery/Components
Industrials
Get the next $SENS alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $SENS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SENS

DatePrice TargetRatingAnalyst
7/19/2023$0.50Underperform
Jefferies
8/19/2021$6.00Buy
HC Wainwright & Co.
More analyst ratings

$SENS
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

    Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to approximately 6,000 global patients GERMANTOWN, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the fourth quarter ended December 31, 2024. Recent Highlights & Accomplishments: Eversense® 365 approved and launched in the U.S. during 2024 as an integrated contin

    $SENS
    Industrial Machinery/Components
    Industrials

  • Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care

    Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world's first and only One Year CGM system SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care GERMANTOWN, Md. and PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) and Ascensia Diabetes Care announce the software integration of SweetSpot™ with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S. This software integration provides endocrinology practices that partner with SweetSpot the ability to continue to improve patient care by seamlessly and regularly reviewing data from patients u

    $SENS
    Industrial Machinery/Components
    Industrials

  • Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference

    GERMANTOWN, Md., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming TD Cowen 45th Annual Health Care Conference, being held in Boston, MA. TD Cowen 45th Annual Health Care Conference Format: Corporate overview and one-on-one meetingsDate: Tuesday, March 4, 2025Time: 3:10 pm ETWebcast: Click here Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company's website at www.senseoni

    $SENS
    Industrial Machinery/Components
    Industrials

$SENS
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SENS
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$SENS
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SENS
 SEC Filings

See more

$SENS
 Financials

Live finance-specific insights

See more

  • Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

    Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to approximately 6,000 global patients GERMANTOWN, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the fourth quarter ended December 31, 2024. Recent Highlights & Accomplishments: Eversense® 365 approved and launched in the U.S. during 2024 as an integrated contin

    $SENS
    Industrial Machinery/Components
    Industrials

  • Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time

    GERMANTOWN, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2024 financial results after market close on Monday, March 3, 2025. Management will hold a conference call to review the Company's fourth quarter and full year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at

    $SENS
    Industrial Machinery/Components
    Industrials

  • Senseonics Holdings, Inc. Reports Third Quarter 2024 Financial Results

    GERMANTOWN, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights & Accomplishments: Eversense® 365 approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetesCommercialization, now in process, driven by Senseonics' global commercial partner, Ascensia Diabetes Care, a subsidiary of PHC Holdings CorporationMercy health system inserted the

    $SENS
    Industrial Machinery/Components
    Industrials

$SENS
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more